# Astellas Pharma Global Development, Inc.: Phase 3 study closed enrollment, 98 enrolled (Chronic Kidney Disease, Renal Anemia)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Astellas Pharma Global Development, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease |
| NCT ID | NCT05970172 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Chronic Kidney Disease; Renal Anemia |
| Intervention types | drug |
| Target enrollment | 98 |
| Site countries | Belgium, Croatia, Denmark, Finland, Germany, Greece, Ireland, Italy, Lebanon, Lithuania, Netherlands, Norway |
| Posted | 2023-08-01 |
| Planned start | 2024-01-16 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-13 |
| Last update posted | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05970172). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.